高剂量玻璃体内阿柏西普8 mg治疗新生血管性年龄相关性黄斑变性的效果:2期CANDELA随机临床试验
CANDELA试验将106只新生血管性年龄相关性黄斑变性眼随机分至阿柏西普8 mg组或2 mg组,主要终点第16周中心凹无液比例分别为50.9%与34.0%(差异17.0个百分点,95%CI -1.6至35.5,P=0.08),未达5%双侧显著性水平;44周内未观察到新的安全性信号,作者认为趋势提示8 mg可能具有额外治疗获益并支持进一步评估。
要点
- 第16周无液比例8 mg组50.9% vs 2 mg组34.0%,差异17.0个百分点(95%CI -1.6至35.5),未达统计学显著。
- 第44周无液比例8 mg组39.6% vs 2 mg组28.3%,差异11.3个百分点(95%CI -6.6至29.2),未达统计学显著。
- 44周内两组安全性特征未见差异,未观察到新的安全性信号。
核心结论
- 阿柏西普8 mg未在第16周达到主要疗效终点(5%双侧显著性水平)。
- 44周观察到的解剖与视力改善趋势提示8 mg相较2 mg可能具有额外治疗获益。
- 44周内未观察到新的安全性信号,作者认为这些发现支持在包括nAMD和糖尿病性黄斑水肿的渗出性视网膜疾病关键试验中进一步评估阿柏西普8 mg。
研究设计与样本
- CANDELA为在美国开展的2期、随机、单盲、开放标签、44周临床试验(ClinicalTrials.gov NCT04126317)。
- 纳入2019年11月至2021年11月间初治的活动性黄斑下脉络膜新生血管继发于nAMD、研究眼最佳矫正视力评分78至24个字母(约20/32至20/320)的患者。
- 符合条件者按1:1随机接受3次每月8 mg(70 μL)或2 mg(50 μL)阿柏西普注射,随后在第20周和第32周给药。
- 共106只合格眼被随机分配至阿柏西普8 mg组(n=53)或2 mg组(n=53);总体66名参与者(62.3%)为女性。
主要发现
- 第16周中心凹无液比例8 mg组50.9%(n=27)vs 2 mg组34.0%(n=18),差异17.0个百分点(95%CI -1.6至35.5),P=0.08。
- 第44周中心凹无液比例8 mg组39.6%(n=21)vs 2 mg组28.3%(n=15),差异11.3个百分点(95%CI -6.6至29.2),名义P=0.22。
- 第44周平均(SE)中心视网膜厚度变化8 mg组-159.4(16.4)μm vs 2 mg组-137.2(22.8)μm,最小二乘均值差异-9.5(95%CI -51.4至32.4),名义P=0.65。
- 第44周平均(SE)最佳矫正视力评分变化8 mg组+7.9(1.5)个字母 vs 2 mg组+5.1(1.5)个字母,最小二乘均值差异+2.8(95%CI -1.4至+7.0),名义P=0.20。
- 两组间安全性特征未见差异。
关键数值与推荐
- 共同主要终点为第16周中心子区域无液(无视网膜内液和视网膜下液)的眼睛比例以及安全性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 阿柏西普8 mg未在第16周达到主要疗效终点(5%双侧显著性水平)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Aflibercept, 8 mg, may have greater therapeutic benefits compared with aflibercept, 2 mg, in patients with neovascular age-related macular degeneration (nAMD), including potentially improved outcomes and decreased treatment burden. OBJECTIVE: To assess safety and efficacy of aflibercept, 8 mg, in patients with nAMD. DESIGN, SETTING, AND PARTICIPANTS: The CANDELA trial was a phase 2, randomized, single-masked, open-label, 44-week clinical trial conducted in the US. Treatment-naive patients with active subfoveal choroidal neovascularization secondary to nAMD and a best-corrected visual acuity score of 78 to 24 letters (approximately 20/32 to 20/320) in the study eye were enrolled between November 2019 and November 2021. INTERVENTIONS: Eligible participants were randomized 1:1 to receive 3 monthly doses of 8 mg (70 μL) or 2 mg (50 μL) of aflibercept followed by doses at weeks 20 and 32. MAIN OUTCOMES AND MEASURES: Coprimary end points were the proportion of eyes without fluid (absence of intraretinal and subretinal fluid) in the central subfield at week 16 and safety. RESULTS: All 106 eligible eyes were randomized to receive aflibercept, 8 mg (n = 53), or aflibercept, 2 mg (n = 53). Overall, 66 participants (62.3%) were female. The proportion of eyes without fluid in the central subfield with 8-mg vs 2-mg aflibercept was 50.9% (n = 27) vs 34.0% (n = 18) (difference, 17.0 [95% CI, -1.6 to 35.5] percentage points; P = .08) at week 16 and 39.6% (n = 21) vs 28.3% (n = 15) (difference, 11.3 [95% CI, -6.6 to 29.2] percentage points; nominal P = .22) at week 44. At week 44, mean (SE) change in central retinal thickness was -159.4 (16.4) vs -137.2 (22.8) μm with 8 mg vs 2 mg of aflibercept, respectively (least squares mean difference, -9.5 [95% CI, -51.4 to 32.4]; nominal P = .65) and mean (SE) change in best-corrected visual acuity score was +7.9 (1.5) vs +5.1 (1.5) letters (least squares mean difference, +2.8 [95% CI, -1.4 to +7.0]; nominal P = .20). No differences in safety profiles between the groups were observed. CONCLUSIONS AND RELEVANCE: Although aflibercept, 8 mg, did not achieve the primary efficacy end point at week 16 at the 2-sided significance level of 5%, the observed trends in anatomic and visual improvements over 44 weeks with aflibercept, 8 mg, indicate potential additional therapeutic benefit over aflibercept, 2 mg. No new safety signals were observed over 44 weeks. These findings support further evaluation of aflibercept, 8 mg, in pivotal trials of exudative retinal diseases including nAMD and diabetic macular edema. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04126317.
引用
- Wykoff CC, Brown DM, Reed K, et al. Effect of High-Dose Intravitreal Aflibercept, 8 mg, in Patients With Neovascular Age-Related Macular Degeneration: The Phase 2 CANDELA Randomized Clinical Trial. JAMA Ophthalmol. 2023. PMID: 37535382. doi:10.1001/jamaophthalmol.2023.2421
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。